Maresin-1 ameliorates hypertensive vascular remodeling through its receptor LGR6

Abstract

Hypertensive vascular remodeling is defined as the changes in vascular function and structure induced by persistent hypertension. Maresin-1 (MaR1), one of metabolites from Omega-3 fatty acids, has been reported to promote inflammation resolution in several inflammatory diseases. This study aims to investigate the effect of MaR1 on hypertensive vascular remodeling. Here, we found serum MaR1 levels were reduced in hypertensive patients and was negatively correlated with systolic blood pressure (SBP). The treatment of MaR1 reduced the elevation of blood pressure and alleviated vascular remodeling in the angiotensin II (AngII)-infused mouse model. In addition, MaR1-treated vascular smooth muscle cells (VSMCs) exhibited reduced excessive proliferation, migration, and phenotype switching, as well as impaired pyroptosis. However, the knockout of the receptor of MaR1, leucine-rich repeat-containing G protein-coupled receptor 6 (LGR6), was seen to aggravate pathological vascular remodeling, which could not be reversed by additional MaR1 treatment. The mechanisms by which MaR1 regulates vascular remodeling through LGR6 involves the Ca²⁺/calmodulin-dependent protein kinase II/nuclear factor erythroid 2-related factor 2/heme oxygenase-1 signaling pathway. Overall, supplementing MaR1 may be a novel therapeutic strategy for the prevention and treatment of hypertension.

Keywords

leucine-rich repeat-containing G protein-coupled receptor 6 / Maresin-1 / omega-3 fatty acids / pyroptosis / vascular remodeling

References

1	TA Gaziano. Cardiovascular disease in the developing world and its cost-effective management. Circulation. 2005;112(23):3547-3553.
2	N Shi, X Mei, SY Chen. Smooth muscle cells in vascular remodeling. Arterioscler Thromb Vasc Biol. 2019;39(12):e247-e252.
3	MW Majesky. Vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2016;36(10):e82-86.
4	M Liu, D Gomez. Smooth muscle cell phenotypic diversity. Arterioscler Thromb Vasc Biol. 2019;39(9):1715-1723.
5	A Frismantiene, M Philippova, P Erne, TJ Resink. Smooth muscle cell-driven vascular diseases and molecular mechanisms of VSMC plasticity. Cell Signal. 2018;52:48-64.
6	E Melton, H Qiu. Interleukin-1β in multifactorial hypertension: inflammation, vascular smooth muscle cell and extracellular matrix remodeling, and non-coding RNA regulation. Int J Mol Sci. 2021;22(16):8639.
7	SB Cau, A Bruder-Nascimento, MB Silva, et al. Angiotensin-II activates vascular inflammasome and induces vascular damage. Vasc Pharmacol. 2021;139:106881.
8	JE Vince, J Silke. The intersection of cell death and inflammasome activation. Cell Mol Life Sci. 2016;73(11-12):2349-2367.
9	DF Horrobin. Low prevalences of coronary heart disease (CHD), psoriasis, asthma and rheumatoid arthritis in Eskimos: are they caused by high dietary intake of eicosapentaenoic acid (EPA), a genetic variation of essential fatty acid (EFA) metabolism or a combination of both? Med Hypotheses. 1987;22(4):421-428.
10	N Saito-Sasaki, Y Sawada, M Nakamura. Maresin-1 and inflammatory disease. Int J Mol Sci. 2022;23(3):1367.
11	W Yang, K Tao, P Zhang, X Chen, X Sun, R Li. Maresin 1 protects against lipopolysaccharide/d-galactosamine-induced acute liver injury by inhibiting macrophage pyroptosis and inflammatory response. Biochem Pharmacol. 2022;195:114863.
12	YH Wang, Y Li, JN Wang, et al. Maresin 1 attenuates radicular pain through the inhibition of NLRP3 inflammasome-induced pyroptosis via NF-κB signaling. Front Neurosci. 2020;14:831.
13	S Tang, C Gao, Y Long, et al. Maresin 1 mitigates high glucose-induced mouse glomerular mesangial cell injury by inhibiting inflammation and fibrosis. Mediators Inflamm. 2017;2017:2438247.
14	CN Serhan. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014;510(7503):92-101.
15	N Chiang, S Libreros, PC Norris, X de la Rosa, CN Serhan. Maresin 1 activates LGR6 receptor promoting phagocyte immunoresolvent functions. J Clin Invest. 2019;129(12):5294-5311.
16	CT Elder, AC Filiberto, G Su, et al. Maresin 1 activates LGR6 signaling to inhibit smooth muscle cell activation and attenuate murine abdominal aortic aneurysm formation. FASEB J. 2021;35(8):e21780.
17	V Leroy, J Cai, Z Tu, et al. Resolution of post-lung transplant ischemia-reperfusion injury is modulated via resolvin D1-FPR2 and maresin 1-LGR6 signaling. J Heart Lung Transplant. 2023;42(5):562-574.
18	H Li, X Li, Y Hao, et al. Maresin 1 intervention reverses experimental pulmonary arterial hypertension in mice. Br J Pharmacol. 2022;179(22):5132-5147.
19	LM Laiglesia, X Escoté, N Sáinz, et al. Maresin 1 activates brown adipose tissue and promotes browning of white adipose tissue in mice. Mol Metab. 2023;74:101749.
20	J Shi, Y Yang, A Cheng, G Xu, F He. Metabolism of vascular smooth muscle cells in vascular diseases. Am J Physiol Heart Circ Physiol. 2020;319(3):H613-h631.
21	MV Olsen, AV Lyngstadaas, JA Bair, et al. Maresin 1, a specialized proresolving mediator, stimulates intracellular [Ca(2+)] and secretion in conjunctival goblet cells. J Cell Physiol. 2021;236(1):340-353.
22	V Fattori, FA Pinho-Ribeiro, L Staurengo-Ferrari, et al. The specialised pro-resolving lipid mediator maresin 1 reduces inflammatory pain with a long-lasting analgesic effect. Br J Pharmacol. 2019;176(11):1728-1744.
23	QM Chen, AJ Maltagliati. Nrf2 at the heart of oxidative stress and cardiac protection. Physiol Genomics. 2018;50(2):77-97.
24	C Tonelli, IIC Chio, DA Tuveson. Transcriptional regulation by Nrf2. Antioxid Redox Signal. 2018;29(17):1727-1745.
25	MC Basil, BD Levy. Specialized pro-resolving mediators: endogenous regulators of infection and inflammation. Nat Rev Immunol. 2016;16(1):51-67.
26	S Jin, H Chen, Y Li, et al. Maresin 1 improves the Treg/Th17 imbalance in rheumatoid arthritis through miR-21. Ann Rheum Dis. 2018;77(11):1644-1652.
27	J Wu, XY Li, X Fang, FY Teng, Y Xu. Decreased serum maresin 1 concentration is associated with postmenopausal osteoporosis: a cross-sectional study. Front Med. 2021;8:759825.
28	X Li, B Xu, J Wu, et al. Maresin 1 alleviates diabetic kidney disease via LGR6-mediated cAMP-SOD2-ROS pathway. Oxid Med Cell Long. 2022;2022:7177889.
29	T Miao, B Huang, N He, et al. Decreased plasma maresin 1 concentration is associated with diabetic foot ulcer. Mediators Inflamm. 2020;2020:4539035.
30	WA Julliard, YPA Myo, A Perelas, PD Jackson, TH Thatcher, PJ Sime. Specialized pro-resolving mediators as modulators of immune responses. Semin Immunol. 2022;59:101605.
31	JR Viola, P Lemnitzer, Y Jansen, et al. Resolving lipid mediators maresin 1 and resolvin D2 prevent atheroprogression in mice. Circ Res. 2016;119(9):1030-1038.
32	HJ Sun, XS Ren, XQ Xiong, et al. NLRP3 inflammasome activation contributes to VSMC phenotypic transformation and proliferation in hypertension. Cell Death Dis. 2017;8(10):e3074.
33	XS Ren, Y Tong, L Ling, et al. NLRP3 gene deletion attenuates angiotensin II-induced phenotypic transformation of vascular smooth muscle cells and vascular remodeling. Cell Physiol Biochem. 2017;44(6):2269-2280.
34	J Gao, Y Chen, H Wang, et al. Gasdermin D deficiency in vascular smooth muscle cells ameliorates abdominal aortic aneurysm through reducing putrescine synthesis. Adv Sci (Weinh). 2023;10(5):e2204038.
35	V Garcia, A Gilani, B Shkolnik, et al. 20-HETE signals through G-protein-coupled receptor GPR75 (G(q)) to affect vascular function and trigger hypertension. Circ Res. 2017;120(11):1776-1788.
36	DM Kaye, WA Shihata, HA Jama, et al. Deficiency of prebiotic fiber and insufficient signaling through gut metabolite-sensing receptors leads to cardiovascular disease. Circulation. 2020;141(17):1393-1403.
37	F Zou, Y Li, S Zhang, J Zhang. DP1 (prostaglandin D(2) receptor 1) activation protects against vascular remodeling and vascular smooth muscle cell transition to myofibroblasts in angiotensin II-induced hypertension in mice. Hypertension (Dallas, Tex : 1979). 2022;79(6):1203-1215.
38	LJ Zhu, PJ Klutho, JA Scott, et al. Oxidative activation of the Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) regulates vascular smooth muscle migration and apoptosis. Vasc Pharmacol. 2014;60(2):75-83.
39	E Cipolletta, S Monaco, AS Maione, et al. Calmodulin-dependent kinase II mediates vascular smooth muscle cell proliferation and is potentiated by extracellular signal regulated kinase. Endocrinology. 2010;151(6):2747-2759.
40	AM Prasad, DA Morgan, DW Nuno, et al. Calcium/calmodulin-dependent kinase II inhibition in smooth muscle reduces angiotensin II-induced hypertension by controlling aortic remodeling and baroreceptor function. J Am Heart Assoc. 2015;4(6):e001949.
41	X Zhang, Y Yu, H Lei, et al. The Nrf-2/HO-1 signaling axis: a ray of hope in cardiovascular diseases. Cardiol Res Pract. 2020;2020:5695723.
42	S Hu, B Liu, M Yang, et al. Carnosic acid protects against doxorubicin-induced cardiotoxicity through enhancing the Nrf2/HO-1 pathway. Food Funct. 2023;14(12).
43	J Gu, H Huang, C Liu, et al. Pinocembrin inhibited cardiomyocyte pyroptosis against doxorubicin-induced cardiac dysfunction via regulating Nrf2/Sirt3 signaling pathway. Int Immunopharmacol. 2021;95:107533.
44	J Zhang, Z Yin, Y Xu, et al. Resolvin E1/ChemR23 Protects Against Hypertension and Vascular Remodeling in Angiotensin II-Induced Hypertensive Mice. Hypertension (Dallas, Tex : 1979). 2023;80(12):2650-2664.
45	G Li, C Liu, L Yang, et al. Syringaresinol protects against diabetic nephropathy by inhibiting pyroptosis via NRF2-mediated antioxidant pathway. Cell Biol Toxicol. 2023;39(3):621-639.
46	J Ye, Q Ji, J Liu, et al. Interleukin 22 promotes blood pressure elevation and endothelial dysfunction in angiotensin II-treated mice. J Am Heart Assoc. 2017;6(10):e005875.
47	Z Wang, Y Xu, M Wang, et al. TRPA1 inhibition ameliorates pressure overload-induced cardiac hypertrophy and fibrosis in mice. EBioMedicine. 2018;36:54-62.
48	J Zhang, M Wang, J Ye, et al. The anti-inflammatory mediator resolvin E1 protects mice against lipopolysaccharide-induced heart injury. Front Pharmacol. 2020;11:203.
49	J Ye, B Que, Y Huang, et al. Interleukin-12p35 knockout promotes macrophage differentiation, aggravates vascular dysfunction, and elevates blood pressure in angiotensin II-infused mice. Cardiovasc Res. 2019;115(6):1102-1113.